Astellas Pharma, a Tokyo, Japan-based company dedicated to develop pharmaceutical products focusing on Urology, Oncology, Immunology, Nephrology and Neuroscience, has partnered with MPM Capital* to launch DigiTx Partners, a digital health investment company.
DigiTx Partners will invest in the digital health space broadly, with a special focus on companies which create solutions that improve patient outcomes and provide substantial synergy with a broader pharma business.
Although the emphasis will be on earlier stage companies, investments will be made in both startups and growth stage companies.
The initiative will be led by CEO David Kim, MD, who has deep investing and operating experience in both the healthcare and digital sectors. He was most recently the Chief Operating Officer of Lumiata, Inc. a venture-backed predictive analytics company.
In addition to prior investment experiences at MPM Capital, Kim served as a Partner at Pinnacle Ventures, investing both equity and venture debt funds, and worked as an equity research analyst at several financial institutions. He is a graduate of Johns Hopkins University School of Medicine (MD) and Stanford Graduate School of Business (MBA).
*MPM Capital is an early-stage life sciences venture investing firm which identifies and builds companies around transformational treatments and cures.